About 50% of women have dense breast tissue. Mammography sensitivity decreases with higher breast density because both cancer and dense breast tissue appear white on mammograms.³
Information for patients
With a cancer diagnosis, early detection means better outcomes. It means hope. But when it comes to breast cancer, a significant portion of women have reduced opportunity for an early, life-saving diagnosis.
That’s why we developed Syantra DX™ Breast Cancer.
You have your own reason for wanting to be sure.
Whether it’s your family, your career, your friends, plans for adventure or all of the above — none of it works without you.
You know that one out of eight women will develop breast cancer in her lifetime.¹ That’s why you take charge of your breast health: you monitor your breasts and maintain a healthy lifestyle. You also know that regular screening is a key part of maintaining breast health.
What you may not know is that for some women, screening by mammograms alone may not be enough.² ³
It's time for a new tool in the battle against breast cancer
For many women, for many reasons, early breast cancer detection through existing screening protocols is reduced.
About half of all women have dense or very dense breasts.
Mammography sensitivity decreases with higher breast density because both cancer and dense breast tissue appear white on mammograms, creating a camouflage effect.²
In Canada, women under 50-years aren’t typically referred for mammography screening. Breast cancer among younger women is less common but still significant. In fact, 18 percent of breast cancer diagnoses are women under age 50.³
A different approach to detection
Syantra DX™ Breast Cancer is a blood test for breast cancer screening. It’s an easy, convenient, and accurate tool that supports womens’ access to early detection.
How does the test work?
Syantra DX™ Breast Cancer is a precision medicine tool that measures a panel of gene expression biomarkers from whole blood. It then uses a software package, developed with machine learning, to interpret data. It provides a molecular approach to breast cancer screening that can detect invasive disease at early stages.
The Syantra DX Breast Cancer screening process
Confidence in our results
Syantra DX™ Breast Cancer has an inferred 98.5% accuracy for women under 50-years-old in ongoing prospective clinical studies.⁴
A changed screening experience
Monitoring your breast health starts with a routine blood draw
Syantra DX™ Breast Cancer is a blood-based diagnostic. Patients simply go for a routine blood collection and then meet with their physician to discuss their test results once they’re ready.
A simple, convenient testing process
Contact us
Interested in learning more about Syantra DX™ Breast Cancer or Syantra Inc.? Contact us through the form below.
Please note:
Syantra DX™ Breast Cancer is a screening test and may be used as part of the regular screening process. There is the potential for false negative and false positive results to occur. All results should be interpreted by a qualified healthcare provider, and no interventional action should be taken based solely on Syantra DX™ Breast Cancer results.
Citations
- SEER Cancer Statistics Review, 1975-2017, 2020.
- DeSantis, C.E. et al., 2019. Breast Cancer Statistics CA: A Cancer Journal for Clinicians. 69: 438.
- Thigpen D, Kappler A, Brem R. The Role of Ultrasound in Screening Dense Breasts-A Review of the Literature and Practical Solutions for Implementation. Diagnostics (Basel). 2018;8(1):20. Hendrick RE, et al, DMIST Investigators Group. Radiology. 2008 Feb; 246(2):376-83. Kolb TM, et al. Radiology. 2002 Oct; 225(1):165-75.
- Syantra DX™ Breast Cancer has been evaluated in clinical studies for women between the ages of 25 to 80. The data infers an accuracy of 92.2% for women between 25 to 80, and 98.5% for women under 50. See IDBC study on clinicaltrials.gov: Bundred, N. et al., A whole blood assay to identify breast cancer: interim analysis of the international identify breast cancer (IDBC) study evidence supporting the Syantra DX Breast Cancer Test, San Antonio Breast Cancer Symposium, 21-A-1625-SABCS, presented December 8, 2021, San Antonio, TX, USA.
